Prevention of RSV in Infants

 Monoclonal Antibodies, Maternal Vaccination, and the End of Palivizumab 

Well-Child Care: Protecting Before the First Winter

Lea este articulo en español: Version Español

In well-child care, few preventive decisions are as time-sensitive as protecting young infants from severe respiratory syncytial virus (RSV) disease during their first months of life. RSV is a respiratory virus that, because of its lower-airway tropism and the infant’s immunologic and airway immaturity, can trigger bronchiolar inflammation, edema, mucus plugging, and small-airway obstruction—producing hypoxemia and respiratory distress. That is the classic bronchiolitis pathophysiology. Epidemiologically, the burden concentrates in early infancy, with strong seasonality and surges that strain hospitals; risk rises in prematurity, congenital heart disease, chronic lung disease of prematurity, and other vulnerable conditions.

The most practice-changing development for preventive pediatrics is the AAP’s consolidation of a new era: palivizumab is no longer routinely recommended and is being discontinued (with a discontinuation date referenced by AAP materials), reinforcing the shift toward newer strategies—especially long-acting monoclonal antibodies such as nirsevimab for eligible infants—and coordinated use with maternal immunization when appropriate (respiratory-syncytial-virus-rsv-prevention) (Recommendations-for-the-Prevention-of-RSV-Disease).   In parallel, CDC clinical guidance clarifies age- and risk-based use (for example, avoiding infant monoclonal antibodies in older children without increased risk, and specific age/season limits) (Vaccine-clinical-infants-young-children).  

Treatment remains largely supportive once bronchiolitis occurs: oxygen, hydration, feeding support, and escalation based on severity. That is precisely why prevention matters: preventing severe infections upstream can reduce hospitalizations, ICU utilization, and downstream complications.

From a pediatrician-epidemiologist’s perspective, this prevention policy has three puericultura implications. First, it shifts the conversation from “what do we do when the baby gets sick?” to “what barrier prevents protection before the seasonal peak?” Second, it demands sharper risk stratification and timing; the right intervention in the right window is worth far more than a late or misapplied one. Third, it illustrates a core epidemiologic principle: when a more effective or scalable preventive tool becomes available, standards evolve, and clinical practice must follow evidence rather than habit. In the clinic, that translates into making RSV prevention a routine, explicit agenda item in newborn and infant well visits, alongside breastfeeding support, safe sleep counseling, and routine immunizations.